This study is looking into a drug called ubamatamab for adults with advanced ovarian, fallopian tube, or primary peritoneal cancer that has grown despite previous platinum-based chemotherapy. Researchers want to understand how safe and effective ubamatamab is, both by itself and when combined with other anti-cancer drugs like bevacizumab, cemiplimab, fianlimab, and PLD (a type of chemotherapy). The main goal is to see if these treatments can shrink tumors. You might be able to join if you are at least 18 years old, a woman, and have measurable cancer that has progressed. The study aims to enroll 220 participants, but its current recruitment status is unclear.

Study design

This interventional study plans to enroll 220 participants. It is testing ubamatamab alone and in combination with other drugs.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The main treatment effect will be measured for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.